ACCP "Excellence in Achievement" 

The ACCP "Excellence in Achievement" Program serves to acknowledge ACCP Members whose engagement with ACCP events/committees and contributions to the organization are deserving of recognition.

Gina Pastino, PhD

Gina Pastino, PhD, DABT, is a Senior Director in the Scientific Affairs – Clinical Pharmacology group at PRA Health Sciences. Dr. Pastino has been a diplomat of the America Board of Toxicology since 1998 and earned a doctorate in pharmacology from the Rutgers Graduate School of Biomedical Sciences, where she was also Adjunct Faculty (2002 – 2020). After completing her doctorate, Dr. Pastino completed a post-doctoral fellowship at the Mount Sinai School of Medicine’s Alcohol Research & Treatment Ctr and was a fellow in the American Association for Advancement of Science in the Science & Technology Fellowship program (1997-1998). Dr. Pastino started her career in the pharmaceutical industry in 2000 at Merck/Schering Plough where she worked for 10 years. Since then, she has been at several mid-sized pharmaceutical companies as a clinical pharmacologist before joining PRA Health Sciences in 2018.

Dr. Pastino’s scientific interest is in clinical drug development and the integration of biomarkers and patients into early clinical pharmacology studies. Her emphasis is on disorders of the central nervous system (neurodegenerative, neuropsychiatric diseases, general neurology, addiction) although she has also supported other therapeutic areas, including drugs in development for the treatment of inflammatory conditions and infectious diseases. Dr. Pastino has published over 21 articles and is a named inventor on patents resulting from her support of the development of the orexin receptor antagonist, lemborexant, for the treatment of insomnia.

Dr. Pastino joined the ACCP in 2015 and has been a member of the Public Policy Committee since 2016, serving as Chair from 2018-2020. She is a reviewer for ACCP's The Journal of Clinical Pharmacology and most recently led the ACCP endorsement of the ASCEPT-BPS joint statement “COVID-19 (SARS-CoV-2): A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 treatments.”

Dr. Pastino kindly shared her thoughts on what ACCP membership means to her:

“I was initially drawn to ACCP because of their strength and quality in education. Of the many professional society meetings I have attended throughout my career, the ACCP meetings are where I have learned the most. The ACCP is a thought leader in the field of clinical pharmacology as demonstrated by the Policy Statements the society has endorsed or developed in recent years and that have demonstrated impact on how drugs are developed. The ACCP brings together scientists from academia, industry and regulatory agencies, as well as clinicians; these complementary profiles allow us to transform the science into modalities for treating patients more effectively. I thoroughly enjoy the opportunity to network with so many impressive and knowledgeable scientists and clinicians.”

Congratulations, Dr. Pastino, on being recognized for your outstanding achievements and contributions to ACCP! We look forward to your continued support.